Daratumumab for Multiple Myeloma
Study Summary
This trial will test the effectiveness of daratumumab and lenalidomide in treating multiple myeloma without the use of steroids.
- Multiple Myeloma
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 466 Patients • NCT03158688Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
What symptoms is Daratumumab typically prescribed to alleviate?
"Daratumumab is generally prescribed as a treatment for ophthalmia, sympathetic. It can also be utilized to address branch retinal vein occlusion and macular edema in patients who have experienced at least two rounds of systemic chemotherapy."
How many participants are being admitted to this clinical research?
"Affirmative. According to information on clinicaltrials.gov, this medical trial is presently seeking participants and was first published on July 27th 2021 with a subsequent update date of July 8th 2022. The research will require 28 individuals at one site for completion."
Have any other investigations been conducted involving Daratumumab?
"Currently, 745 studies are in progress for Daratumumab with 169 of them classified as Phase 3. Most experiments occur in Joliet, Illinois although there are 26198 locations worldwide running trials involving this medication."
Am I eligible to contribute to this research endeavor?
"This clinical research is searching for 28 individuals between 18 and 75 with multiple myeloma. In addition to this, the participants must be newly diagnosed, surgically sterile or post-menopausal (if female), not have received therapy before, and have a performance status of 3 or less in order to qualify."
Is there any risk associated with Daratumumab treatments?
"While there is a limited data set to support the safety of daratumumab, no evidence exists that demonstrates efficacy. So, our team at Power rated it as a 2 on their scale from 1 to 3."
Are participants over the age of sixty eligible for enrollment in this research project?
"This research is targeting individuals between 18 and 75 years of age."
Is it currently feasible for volunteers to join this experiment?
"Correct. Clinicaltrials.gov information indicates that this trial is actively recruiting, with the first listing being published on July 27th 2021 and recently edited on July 8th 2022. They are searching to enroll 28 individuals from one site location."